Welcome to our dedicated page for Sono Tek SEC filings (Ticker: SOTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sono-Tek Corporation (Nasdaq: SOTK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sono-Tek is incorporated in New York, and its recent filings include multiple current reports on Form 8-K and a definitive proxy statement on Schedule 14A, all of which help investors understand the company’s operations, governance, and material events.
Recent Form 8-K filings for Sono-Tek cover results of operations and financial condition, including quarterly earnings releases, as well as material orders such as multi-million dollar medical device coating system contracts. Other 8-Ks report on shareholder meeting presentations and voting outcomes, including director elections, auditor ratification, and advisory votes on executive compensation and the frequency of such votes.
The company’s definitive proxy statement (DEF 14A) outlines matters submitted to shareholders at the annual meeting, such as the election of directors and approval of auditors, and provides detail on governance structure and compensation policies. Together with periodic reports not listed here, these filings form the core regulatory record for SOTK.
On Stock Titan, Sono-Tek’s filings are updated in near real time from the SEC’s EDGAR system. AI-powered summaries help explain the key points of lengthy documents, so readers can quickly see what changed in a quarter, how large orders are disclosed, or how shareholder votes were cast. Users can review 8-Ks for earnings and major contracts, proxy materials for governance information, and other filings to build a fuller picture of Sono-Tek’s financial reporting, risk disclosures, and corporate actions.
Sono-Tek Corp director Lawal Adeniyi reported two related transactions. He bought 2,400 shares of common stock at $4.12 per share in an open-market purchase and simultaneously disposed of 2,400 stock options back to the company at the same price. Following these moves, he holds 2,400 common shares directly and 9,951 options on Sono-Tek stock.
Sono-Tek Corporation reported improved profitability for its third quarter of fiscal 2026 despite nearly flat sales. Net sales for the quarter were $5.0 million, down 3.6% from $5.19 million a year earlier, but gross margin expanded to 50% from 45% as product mix shifted toward higher-margin systems and U.S. sales with lower distributor discounts. Operating income rose to $319,000, up 61% from $198,000, and net income increased 24% to $340,000.
For the first nine months of fiscal 2026, revenue was essentially flat at $15.3 million, while net income grew 32% to $1.25 million as gross profit improved to $7.77 million and gross margin reached 51%. The company ended the period with no debt and cash, cash equivalents and marketable securities totaling $12.26 million, and reported a record combined equipment and service backlog of $12.26 million, up 16% year over year. Shares outstanding were 15,710,389 as of January 9, 2026.
Sono-Tek Corporation filed a current report to notify investors that it has released a press release with its financial results for the quarter ended November 30, 2025. The press release is included as Exhibit 99.1 to the report and provides details on the company’s results of operations and financial condition for that quarter.
The company notes that the information in the furnished exhibit, including the press release, is being provided under Regulation FD and is not considered filed for liability purposes under the Securities Exchange Act. The report is signed by the company’s Chief Financial Officer, Stephen J. Bagley.
Sono-Tek Corporation furnished a press release announcing financial results for the quarter ended August 31, 2025. The company reported this under Item 2.02 and included Regulation FD disclosure under Item 7.01. The release is attached as Exhibit 99.1 and is designated as “furnished,” not “filed,” under the Exchange Act.
Sono‑Tek (SOTK) disclosed an insider transaction. Director Christopher Coccio sold 12,320 shares of common stock on 10/23/2025 at a weighted average price of $4.7803 (Transaction Code: S). Following the sale, he beneficially owns 309,447 shares, held directly.
The footnote states the sale was executed in multiple trades at prices ranging from $4.77 to $4.89, and detailed trade breakdowns are available upon request.
Sono-Tek (SOTK) director Christopher Coccio reported open-market sales of common stock. On 10/21/2025, he sold 100 shares at $4.665, 100 shares at $4.67, 2,097 shares at $4.66, and 2,015 shares at $4.65. Following these transactions, he beneficially owns 321,767 shares, held directly.
This is a routine Form 4 disclosure of insider transactions and changes in direct ownership.
Sono-Tek (SOTK) reported Q2 FY26 results with net sales of $5,163,000 and diluted EPS of $0.03. Gross profit was $2,590,000 with a 50.2% gross margin. Operating income rose to $421,000, a 47% increase year over year as higher-margin mix and lower operating expenses helped results.
Medical sales grew 150% on balloon coating shipments, while Alternative/Clean Energy was steady and Electronics/Microelectronics held near prior-year levels. APAC revenue increased 153% driven by medical and energy orders, partially offsetting a 22% decline in the U.S. and Canada. Backlog was $11,210,000 at August 31, 2025, up 50% sequentially from Q1.
For the first half, sales were $10,296,000 and operating income $905,000 (up 73%). Cash, cash equivalents and marketable securities totaled $10,568,000 with no outstanding debt. Operating cash flow was $(1,099,000), reflecting higher accounts receivable tied to revised timing on a $4.4 million multi-unit order.
Sono-Tek Corporation reported via an 8-K that it issued a press release announcing an order for medical device coating systems valued at $2.8 million.
The disclosure was furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure) and includes Exhibit 99.1, a press release dated October 13, 2025. The furnished information is not deemed filed under Section 18 of the Exchange Act.
Sono-Tek Corporation filed an 8-K announcing that it issued a press release with financial results for the quarter ended August 31, 2025. The release is furnished as Exhibit 99.1 and relates to Items 2.02 (Results of Operations and Financial Condition) and 7.01 (Regulation FD).
The company states the information furnished under Item 7.01, including Exhibit 99.1, is not deemed “filed” under Section 18 of the Exchange Act and is not incorporated by reference into other filings. The press release is dated October 14, 2025.
Sono-Tek Corporation reported that it issued a press release announcing an order for medical device coating systems valued at over $5 million. The company described this order in a report about its results of operations and financial condition and as a Regulation FD disclosure.
The press release, dated September 3, 2025 and attached as an exhibit, provides additional details on the order. The information in this report and the exhibit is being furnished rather than filed, meaning it is not subject to certain liability provisions of the securities laws or automatically incorporated into other company reports.